Day: 17 11 月, 2025

JAKARTA, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) - Indonesia's state-owned social security agency PT TASPEN (Persero) has reiterated its commitment to ensuring social protection for all Indonesian Civil Servants and State Officials, including those stationed abroad.President Director Taspen, Rony Hanityo (2nd left) delivers Work Accident Security Program benefits to the wife of the late Zetro Leonardo Purba, Junior Chancellery Officer at the Indonesian Embassy in Lima, Peru, who died while performing official duties on Sept 1, 2025.The statement follows TASPEN's recent distribution of Work Accident Security Program (Jaminan Kecelakaan Kerja/JKK) benefits to the family of the late Zetro Leonardo Purba, a Junior Chancellery Officer at the Indonesian Embassy in Lima, Peru, who died while performing official duties on September 1, 2025.TASPEN Corporate Secretary Henra expressed condolences to the bereaved family and underscored the agency's role in upholding the state's responsibility to protect civil servants serving anywhere in the world."TASPEN expresses its deepest condolences on the passing of Mr. Zetro Leonardo. The distribution of these benefits is proof that TASPEN carries out its state mandate with integrity and accountability. It is our responsibility to ensure that every civil servant's dedication — even at the farthest corners of the world — is accompanied by a sense of security for them and their families. The state's protection knows no borders," said Aprianto.As of September 30, 2025, TASPEN has provided JKK benefits to 221 heirs of Indonesian civil servants, including those serving on overseas assignments — a reflection of the government's continued commitment to the welfare of public sector workers worldwide.Comprehensive Protection for Civil Servants and FamiliesThe assistance provided to Mr. Purba's family includes Old-Age Savings Program (Tabungan Hari Tua/THT) and Work Accident Security Program benefits, such as Death Benefits/Bereavement Benefits, Death Compensation, and Funeral Benefit. In addition, Scholarship Benefit has been granted for two of his children to support their continued education — part of TASPEN's broader effort to ensure long-term family welfare.The Work Accident Security Program (JKK) forms part of Indonesia's national social protection framework for civil servants and state officials who experience work-related accidents, occupational illnesses, or death while performing state duties — whether domestically or abroad.Four Key Programs Supporting Civil ServantsTASPEN manages four major programs designed to create an integrated and sustainable social security system for civil servants:1. Old-Age Savings Program (THT): A savings and protection plan for employees nearing retirement or their families in case of death before retirement.2. Pension Program: Guarantees a regular post-retirement income as recognition of civil servants' long-term service.3. Work Accident Security Program (JKK): Covers the risk of workplace injuries, illnesses, or death occurring in the line of duty, including while serving abroad.4. Death Security Program (Jaminan Kematian/JKM): Provides compensation and educational scholarships for the families of civil servants who pass away from non-work-related causes.These programs establish a comprehensive social safety net that protects civil servants throughout their professional and personal lives. TASPEN's initiatives reflect the Indonesian government's principle that public service deserves lifelong protection — regardless of where it is carried out. By extending coverage beyond national boundaries, the TASPEN ensures that Indonesian civil servants serving on global missions receive the same level of welfare assurance as those at home.Through adaptive and accountable management, TASPEN continues to play a strategic role as a partner of the Indonesian government in strengthening the welfare and security of civil servants worldwide.About PT TASPEN (Persero)PT TASPEN (Persero) or the Civil Servant Savings and Insurance Fund is an Indonesian state-owned enterprise engaged in retirement savings insurance and pension funds for civil servants (ASN) and state officials. Established on April 17, 1963, PT TASPEN (Persero) plays an active role in social welfare, particularly for civil servants in Indonesia. PT TASPEN (Persero) currently offers several products and services, namely the Work Accident Security Program (JKK), Death Security Program (JKM), Old-Age Savings Program (THT), and Pension Program.PT TASPEN (Persero) is currently the First Chairman of the Asian Civil Service Pension Association (ACSPA), which is the first Association of Social Security Administrators for Civil Servants in Asia, with members consisting of Social Security Administrators for ASN from various countries in Asia, including Indonesia, South Korea, the Philippines, Thailand, and Cambodia. PT TASPEN (Persero) prioritizes the comfort and safety of its participants by implementing the digital superapp service Andal by TASPEN.For information, you can contact the Call Center at 1500919, visit the official website www.taspen.co.id, tcare.taspen.co.id, and all official social media accounts of PT TASPEN (Persero). Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAIPEI, TAIWAN, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) - OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology.Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma.To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to experimental therapies that have the potential to treat these diseases. In the United States, a rare disease is defined as any condition that affects fewer than 200,000 patients. After granting Orphan Drug Designation, the US FDA qualifies companies or drug developers incentives such as tax credits for clinical trials, exemption from user fees, and marketing exclusivity2.In August 2025, OBI launched a phase I/II clinical trial in the United States and Taiwan, recruiting patients with advanced solid tumors. The objectives of the trial are to study the safety, pharmacokinetics, and preliminary efficacy profile of OBI-902 in these patient populations.Heidi Wang, Ph.D, OBI Pharma's Chief Executive Officer noted, "Based on our preclinical data, OBI-902 has several important advantages over other TROP2 ADCs either approved or in development; including high stability in blood circulation, excellent bystander effect that extends the killing to neighboring cancer cells lacking TROP2 expression, potential ability to overcome drug resistance, and outstanding activity in animal and organoid models of cancer. Importantly, this marks the first time an ADC that incorporates OBI's proprietary GlycOBI® ADC technology is being evaluated in patients, including those diagnosed with cholangiocarcinoma. We look forward to investigating this potential best-in-class TROP2 ADC in the clinic."About OBI-902OBI-902 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumor cells and with a drug-antibody ratio (DAR) of 4. TROP2 is highly expressed in a variety of solid tumors such as breast, lung, biliary, bile duct (cholangiocarcinoma), ovarian, gastric, and many other cancer types, rendering it an ideal target for cancer therapy.OBI-902 is a novel site-specific glycan-conjugated ADC using OBI's proprietary GlycOBI platform, which provides improved stability and enhanced hydrophilicity. OBI-902 demonstrated remarkable antitumor efficacy, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. The IND of OBI-902 was cleared by the US FDA on April 30, 2025.Since December 2021, OBI has been granted by Biosion, Inc. (www.biosion.com) an exclusive, worldwide (except in China) license to a TROP2 targeting antibody amino acid sequence. Biosion holds exclusive rights to that antibody sequence in China. OBI holds worldwide commercial rights to OBI-902, except for the rights pertaining to the antibody in China.About GlycOBI®OBI has developed a unique clinical stage, glycan-based site-specific ADC technology (GlycOBI®), which is in a ‘Plug and Play' format and compatible with any antibodies, linkers, and payloads in drug-antibody ratio (DAR) up to 16. Utilizing OBI's proprietary dual-function enzyme (EndoSymeOBI®) and linker technology (HYPrOBI®), homogenous ADCs are manufactured with an efficient and scalable process under GMP conditions. The conjugation process of GlycOBI® avoids disrupting the antibody structure and ensures the ADC has similar biophysical characteristics to the native antibody. Furthermore, OBI's linker technology has improved conjugation efficiency of the payload, reduced aggregation propensity, which provides advantages on manufacturing ADC products. GlycOBI® conjugated ADCs have overcome the limitations of traditional ADCs and achieved better antitumor activity and stability in various in vivo animal studies. GlycOBI®, EndoSymeOBI®, and HYPrOBI® are part of the armamentarium of OBI's Obrion™ ADC Enabling Technologies that also include ThiOBI® and GlycOBI DUO™. OBI-902 is the first ADC utilizing OBI's Obrion™ ADC enabling technology for evaluation of safety and efficacy in Cancer, currently under Phase I/II clinical trial in the US and Taiwan.About OBI PharmaOBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop novel therapeutic agents for patients with high unmet medical needs.OBI's primary focus is the development of novel ADCs, including the first-generation cysteine-based TROP2 ADC, OBI-992. Using the company's proprietary ADC enabling technology, GlycOBI®, powered by EndoSymeOBI® and HYPrOBI®; OBI has created its next-generation novel ADC pipeline, including monospecific: OBI-902 (TROP2), OBI-904 (Nectin-4), bispecific single payload (HER2 x TROP2), and bispecific, dual payload (cMET x HER3) ADCs. To broaden the applicability of linker technology, HYPrOBI®, OBI further developed a novel ThiOBI® platform to enable irreversible cysteine-based conjugation. Additionally, OBI's pipeline includes the first-in-class AKR1C3-targeted small-molecule prodrug OBI-3424, which selectively releases a potent DNA-alkylating antitumor agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme that is highly expressed in tumors. Additional information can be found at www.obipharma.com.GlycOBI®, EndoSymeOBI®, ThiOBI® and HYPrOBI®are registered trademarks of OBI Pharma. Obrion™ and GlycOBI DUO™ are trademarks under registration.1 National Institute of Health for Rare Diseases. Sept. 2025https://rarediseases.info.nih.gov/diseases/9304/cholangiocarcinoma2 US FDA website. Designating an Orphan Product: Drugs and Biological Products Sept.25 https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-productsForward-Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.COMPANY CONTACT:Kevin Poulos, Chief Business OfficerOBI Pharma USA, Inc.+1 (619) 537 7698, ext. 102kpoulos@obipharma.comSOURCE: OBI Pharma USA, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

台北，台湾, 2025年11月17日 - (亚太商讯 via SeaPRwire.com) - 浩鼎（4174.TWO）宣布，收到美国食品药品监督管理局（US FDA）通知，其TROP2靶向ADC新药OBI-902已获准用于治疗胆管癌（Cholangiocarcinoma）的“孤儿药（Orphan Drug Designation）”资格认定。OBI-902为浩鼎自主研发、采用糖位点特异性偶联技术的新型ADC。胆管癌是一种罕见且致死率高的恶性肿瘤，在美国的患者人数少于五万人。根据疾病分期、组织类型及发病部位不同，其五年生存率约为2%至23%¹。目前，美国FDA尚未批准任何用于胆管癌的ADC药物上市销售。为鼓励企业开发治疗罕见疾病的新药，美国FDA设立了“孤儿药”资格认定制度。符合条件的潜在新药经审核通过后，可获得多项政策支持，包括临床支出税务优惠、注册申请费用减免，以及市场独占期等²。在美国，罕见疾病被定义为患者人数少于二十万人的疾病。浩鼎已于2025年8月在美国及台湾启动OBI-902 I/II期临床试验，招募晚期实体瘤患者，旨在评估该药物的安全性、药代动力学特征及初步疗效。浩鼎首席执行官王慧君博士表示：“基于临床前研究，OBI-902相比已上市或研发中的其他TROP2 ADC展现了多项优势，包括在血液循环中具有高稳定性、具备对周围未表达TROP2癌细胞的杀伤能力（旁观者效应），并具备克服耐药性的潜力。在动物试验和类器官肿瘤模型中均表现出优异的药物活性。更重要的是，这是浩鼎首次在临床上应用独家专利GlycOBI® ADC关键技术，其中包含胆管癌患者。我们期待临床试验进一步证实OBI-902具备成为同类最佳（best-in-class）的潜力。”About OBI-902OBI-902 是一款以 TROP2 为靶向的抗体-药物偶联物（ADC）新药，携带强效拓扑异构酶 I 抑制剂用于杀伤肿瘤细胞，药物抗体比例（Drug-Antibody Ratio, DAR）为 4。TROP2 在乳腺癌、肺癌、胆道癌（胆管癌）、卵巢癌、胃癌等多种实体瘤中均呈高表达，被视为理想的抗癌靶点。OBI-902 采用浩鼎专利 GlycOBI® 糖位点特异性技术，具备良好的稳定性和亲水性。在多种动物模型中显示出显著的抗肿瘤功效、良好的安全性及优异的药代动力学特性。其临床试验申请（IND）已于 2025 年 4 月 30 日获美国 FDA 批准。浩鼎于 2021 年 12 月自博奥信生物技术公司（Biosion, Inc., www.biosion.com）引进 TROP2 抗体。根据合约条款，博奥信保留该抗体在中国境内的相关权利。除中国境内抗体权利外，浩鼎拥有 OBI-902 的全球商业化权利。About GlycOBI®浩鼎开发的 GlycOBI® 糖位点特异性 ADC 技术已应用至临床阶段，具备“即插即用”特性，可兼容多种抗体、连接子（linkers）和药物（payloads），其 DAR 可高达 16。透过自主研发的双功能酶 EndoSymeOBI® 及高亲水性连接子技术 HYPrOBI®，可在 GMP 工艺下高效量产均一化 ADC。该偶联过程可避免破坏抗体结构，同时确保 ADC 具备与天然抗体相似的生物特性。HYPrOBI® 高亲水性连接子可提高偶联效率、降低生产过程中不均匀聚集风险，使 ADC 制程具更高优势。多项动物实验显示，采用 GlycOBI® 偶联的 ADC 在抗肿瘤活性与稳定性上均优于传统 ADC。GlycOBI®、EndoSymeOBI® 和 HYPrOBI® 属于浩鼎 Obrion™ ADC 专利技术组合的一部分，另包含 ThiOBI® 与 GlycOBI DUO™。OBI-902 为首款采用 Obrion™ ADC 关键技术进入临床评估的新药，目前已在美国及台湾开展 I/II 期临床试验，以评估其在癌症治疗中的安全性和疗效。About OBI Pharma浩鼎（OBI Pharma, Inc.）成立于 2002 年，总部位于台湾，是一家产品已进入临床阶段的全球肿瘤新药研发公司。浩鼎及其全资子公司 OBI Pharma USA, Inc. 的使命，是研发创新抗癌药物，为具有高度未满足医疗需求的患者提供新的治疗选择。浩鼎的研发核心聚焦于新型抗体-药物偶联物（Antibody-Drug Conjugates, ADC），包括第一代半胱氨酸偶联 TROP2 ADC：OBI-992。通过专利 ADC 关键技术 GlycOBI®，结合 EndoSymeOBI® 和 HYPrOBI®，浩鼎已建立下一代 ADC 产品布局，包括：单抗 ADC：OBI-902（TROP2）、OBI-904（Nectin-4）双抗单药 ADC：HER2 × TROP2双抗双药 ADC：cMET × HER3为拓展 HYPrOBI® 在连接子领域的应用范围，浩鼎进一步开发新型 ThiOBI® 平台，实现不可逆的半胱氨酸偶联能力。此外，浩鼎产品线亦包含全球首创 AKR1C3 靶向小分子前药 OBI-3424，该药物可在肿瘤中过表达的醛酮还原酶（AKR1C3）作用下选择性释放强效 DNA 烷基化剂以治疗癌症。更多信息请参阅： www.obipharma.com 。GlycOBI®、EndoSymeOBI®、ThiOBI® 和 HYPrOBI® 为浩鼎注册商标。Obrion™ 与 GlycOBI DUO™ 为申请中商标。1 National Institute of Health for Rare Diseases. Sept. 2025https://rarediseases.info.nih.gov/diseases/9304/cholangiocarcinoma2 US FDA website. Designating an Orphan Product: Drugs and Biological Products Sept.25 https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products媒体联系：陈祈宏 Derek Chen公共事务部 负责人 | Head of Public Affairs台灣浩鼎（OBI Pharma, Inc.）M: +886-939-797-803 | T: +886-2-2655-8799 Ext. 223derekchen@obipharma.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

新加坡, 2025年11月17日 - (亚太商訊) - SuperX AI Technology Limited (纳斯达克: SUPX)（简称"SuperX"或"公司"），一家全栈式 AI 基础设施解决方案提供商，今日宣布任命黄陈宏博士为公司董事局主席、执行董事兼首席执行官，该任命自 2025 年 12月 1 日起生效。随着全球 AI 计算需求的持续增长，企业对集成化、高能效的基础设施解决方案需求激增。此次任命正值SuperX发展的重要阶段，公司将继续推进其全球扩张工作。董事会相信，经验丰富的领导层将支持公司执行其战略优先事项的能力。这一战略性任命标志着SuperX在成为全球人工智能基础设施领导者的征程中迈出了关键一步。此举不仅为公司带来了黄博士数十年的高管领导经验，同时也将加强其经营管理和公司治理。此次委任旨在通过黄博士卓越的领导力和深厚的行业积淀，加速推进公司构建全球化的全栈式模块化AI工厂的宏伟蓝图。在此之前，公司也于2025年11月11日任命Frank Han为执行董事，以及Roy Rong为独立董事。Frank Han曾任黑石集团资深合伙人，此前还曾在凯雷集团美国收购部、高盛亚洲特殊情况部和麦肯锡公司任职。Roy Rong目前担任TikTok及全球职能部门的财务业务合作伙伴负责人。他曾担任魔古科技（纽约证券交易所代码：MOGU）和车车集团（纳斯达克代码：CCG）的独立董事和审计委员会主席，并在Yixia Technology Co., Ltd.、Quixey Inc.、UC Web、乡村基（中国）餐饮管理有限公司（纽约证券交易所代码：CCSC）、谷歌、Soletron和Sibel Systems等公司担任首席财务官和财务管理职务。黄陈宏博士：引领SuperX开启AI基础设施新篇章的资深领航者黄陈宏博士是一位资深的企业技术领袖，拥有三十年成功领导并扩展跨国公司各类主营业务的辉煌经验。他的加入，是SuperX为提升战略执行、实现全球扩张而做出的极具前瞻性的决策，与SuperX构建端到端AI基础设施的使命深度契合。规模化复杂技术运营的卓越专长：黄博士曾担任SAP全球执行副总裁兼大中华区总裁，以及戴尔大中华区董事长兼总裁，成功管理和扩展了全球最复杂的企业技术业务。该经验使他深谙如何在全球范围内构建和管理高度复杂的运营体系。SuperX致力于打造一个覆盖全球的"AI工厂"蓝图，这一前所未有的挑战，正是黄博士多年积累的规模化运营经验和卓越领导力的用武之地。他也将引领SuperX在全球范围内高效、有序地推进AI基础设施的部署，期望为公司带来可预见的规模效应和增长回报。深厚的数据中心基础设施与电源方案专业背景： 在担任施耐德电气旗下APC大中华区总裁期间，黄博士积累了数据中心电力和冷却基础设施领域的关键实践经验和专业知识。这对于SuperX而言至关重要，因为高性能AI的基石正是稳定、高效的基础设施，特别是其专有的液冷解决方案。黄博士的专业背景将帮助SuperX优化其核心技术，确保为客户提供绿色、高性价比的计算能力。核心网络与技术能力的坚实根基： 黄博士早期在Tellabs和北电网络（Nortel Networks）的任职经历，赋予了他深厚的网络技术功底和管理经验。这将为他领导SuperX这家植根于"硬件+软件+服务"全栈模式的公司奠定坚实基础，确保公司在技术创新和整合方面保持优势。黄陈宏博士表示： "我非常荣幸能在AI的黄金时代领导SuperX。当前市场需求正迅速从单一组件转向集成化、端到端且能快速大规模部署的解决方案——我们将其定义为‘AI工厂’。SuperX拥有清晰的战略愿景和具有颠覆性的集成技术。我的首要任务是聚焦运营执行，加速我们全栈AI基础设施的全球部署，将SuperX打造成为AI基础建设领域当之无愧的全球领导者，为股东创造长期可持续的价值。"黄陈宏博士简介黄陈宏博士是一位经验丰富的技术高管，拥有超过30年的全球企业软件、云计算和IT基础设施公司领导经验。自2025年4月起，他担任中国领先的企业软件公司用友的董事会成员，此前于2025年1月至3月担任该公司总裁。在此之前，黄博士于2021年8月至2024年12月担任SAP全球执行副总裁兼大中华区总裁，期间他负责推动云业务收入的显著增长。2014年10月至2021年8月，他担任戴尔大中华区董事长兼总裁，指导戴尔在该地区的业务拓展，并领导了EMC收购后的整合工作。黄博士早年曾在施耐德电气旗下的APC公司、泰乐公司和北电网络公司担任高级领导职务，包括APC大中华区总裁、珠海Uniflair董事长、泰乐中国区总裁以及北电网络中国区运营商销售总裁。黄博士拥有德克萨斯农工大学电气工程博士学位、复旦大学硕士学位和复旦大学物理学学士学位。黄博士是美国公民。关于SuperX AI Technology Limited（纳斯达克代码：SUPX）SuperX AI Technology Limited 是一家人工智能基础设施解决方案提供商，为人工智能数据中心提供全面的产品组合，包括专有硬件、先进软件以及端到端的服务。公司的服务涵盖先进的解决方案设计与规划、高性价比的基础设施产品集成，以及端到端的运营与维护。其核心产品包括高性能AI服务器、800伏直流（800VDC）解决方案、高密度液冷解决方案，以及AI云和AI智慧体。公司总部位于新加坡，为全球的机构客户提供服务，包括大型企业、研究机构、云及边缘计算部署等。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- The 15th Asian Logistics, Maritime and Aviation Conference (ALMAC) opened today under the theme “Collaboration and Growth in the New Trade Landscape”- The event brings together over 80 heavyweight speakers to explore industry trends and opportunities, driving high-quality development in logistics and supply chain management- New thematic sessions spotlight the Middle East and Central Asia markets, with speakers sharing the latest developments and future opportunities, analysing key strategies and investment directions- John Lee, Chief Executive of the HKSAR, and Almaz Turgunbaev, Deputy Minister of Transport and Communications of the Kyrgyz Republic, attended the Special Address session on the first day of the conference. Their participation aims to deepen international exchange and cooperation, helping to further enhance Hong Kong’s position as an international shipping and aviation hub and its roles as a “superconnector” and “super value-adder”.HONG KONG, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) – The 15th Asian Logistics, Maritime and Aviation Conference (ALMAC), organised by the Hong Kong Special Administrative Region (HKSAR) Government and the Hong Kong Trade Development Council (HKTDC), opened today (17 November) and runs for two days at the Hong Kong Convention and Exhibition Centre. Under the theme “Collaboration and Growth in the New Trade Landscape”, the conference aligns with recommendations in the 15th Five-Year Plan to enhance Hong Kong’s status as an international shipping centre, and policies laid out in the Policy Address to strengthen the development of the shipping, aviation and logistics sectors in the city. As the industry’s annual flagship event, the two-day conference gathers over 80 distinguished speakers, including government officials and industry leaders, to discuss trends and opportunities and promote high-quality development in logistics and supply chain management.John Lee, Chief Executive of the HKSAR, attended the first day of the conference to deliver a Special Address. In addition, this year’s ALMAC invited Central Asian official Almaz Turgunbaev, Deputy Minister of Transport and Communications of the Kyrgyz Republic, to also deliver a Special Address.John Lee said: “The conference theme this year, ‘Collaboration and Growth in the New Trade Landscape’, is a timely response to rising geopolitical tensions and the volatile global trade policies, which present considerable challenges for our maritime, aviation and logistics industries, from route planning and shipping fleet deployment to inventory and warehouse management. Nevertheless, as the Chinese saying goes, ‘where there are challenges, there are opportunities’. Geopolitical risks can be overcome by market diversification. Increased costs related to supply chain concerns can be offset, at least partially, by technology-enabled efficiencies.”Mr Lee also shared: “I am particularly pleased to announce that Hong Kong has established Partner Port relationships with Guangxi port and Dalian port in the Chinese Mainland, and Port San Antonio in Chile. These ports are of strategic importance, and true to our character and policy priorities. As an international maritime centre, we connect the Chinese Mainland with the world and seek partners who support an open, international trade order.”In her welcome remarks, Sophia Chong, Executive Director of the HKTDC, said: “Now is the perfect time to embrace new possibilities, as trade networks and supply chains around the world undergo a sweeping transformation. The ever-changing trade polices of major economies continue to keep business agile. At the same time, the world is being rapidly reshaped by technological advances – particularly the digitalisation of trade – and a growing industry-wide commitment to sustainability. Hong Kong, as a major hub for aviation, shipping, logistics and supply chain management, is at the forefront of these changes. The HKTDC remains committed to leveraging the city’s unique strengths to help businesses establish resilient and sustainable supply chains, while reinforcing Hong Kong’s role as a superconnector and super value-adder.”Strengthening Hong Kong’s logistics hub role and promoting regional cooperationRecommendations in the 15th Five-Year Plan to support the consolidation and enhancement of Hong Kong’s status as an international shipping centre carry profound strategic significance. The HKTDC will continue to deepen Hong Kong’s role as an international exchange platform, facilitating connections and substantive cooperation between local and overseas industries, assisting enterprises in “going global”, helping to expand their businesses in global markets, and enhancing their competitiveness. A key focus is promoting trade linkages and actively encouraging enterprises to leverage the HKTDC’s trade platforms and events to achieve greater cooperation across industries. This year’s ALMAC continues to feature business-matching sessions, connecting shippers with service providers to foster regional partnerships and drive industry growth.ALMAC this year features exhibition zones dedicated to aviation, the low-altitude economy, technology, supply chain management and logistics services as well as maritime and port services. Over 90 exhibitors are showcasing the latest leading logistics and supply chain solutions. Notably, the Low-altitude Economy zone makes its debut at ALMAC, with enterprises from the Regulatory Sandbox pilot projects – including SF Express (Hong Kong) and Esri China (Hong Kong) Limited –demonstrating cutting-edge technologies and applications in drones, unmanned aerial vehicles (UAVs) and urban air mobility (UAM), promoting awareness of the latest innovations and applications in this fast-rising sector.Three key trends in focus; unlocking opportunities in the Middle East and Central AsiaThis year’s ALMAC focuses on three key trends: supply chain diversification, sustainability and green energy and innovation and technology, highlighting Hong Kong’s critical role in global connectivity.On the first day, the key session “Insights into a New Era of Global Trade: Driving Business Growth” will feature international industry leaders from SEKO Logistics, GEODIS, and Mattel who will explore the challenges and opportunities arising from changes in trade policies and economic fragmentation. Newly launched thematic sessions will focus on the potential of the Middle Eastern and Central Asian markets. In the Middle East Session, representatives from Etihad Airways, DP World Logistics and the Qatar Free Zones Authority will share insights on logistics innovation and investment strategies. The Central Asia Session will engage representatives from QazTrade Center for Trade Policy Development, JSC, under the Ministry of Trade and Integration of the Republic of Kazakhstan, Shyngar Trans Logistics Company, the Organisation for Economic Co-Operation and Development and PTC. The discussion will address regional supply chain development and the advantages of multimodal transport.Low-altitude economy and smart ports: reshaping the air and maritime transport landscapeIn the first-day session “The Engine of Low-altitude Economy: How Cargo Drones Are Revolutionising the Future of Air Logistics”, Manal Habib, CEO and Founder, MightyFly; Bobby Healy, CEO and Founder, Manna; Kenny Lau, Chief Technology Officer, SF Express (Hong Kong) Limited; Ryan Walsh, Founder and CEO, Valqari; and Andrea Wu, CEO, Urban-Air Port Ltd, shared the latest breakthroughs in drone freight design, automation and AI-driven logistics systems. Meanwhile, the Low-altitude Economy zone at the conference is showcasing drones and related applications, allowing participants to experience first hand the future of air transport and explore the potential of low-altitude economy innovations in the logistics sector.In addition, the Port Community System X LSCM Maritime Summit 2025 will focus on the future development of smart ports and smart trade. The summit will explore how applying the Port Community System (PCS) can significantly enhance operational efficiency and supply chain visibility through cutting-edge technologies such as AI, blockchain and the Internet of Things. It will also showcase Hong Kong’s unique advantages as an international shipping centre and a hub for smart trade. Conference and workshops support enterprises’ green transformationA first-day workshop, “Sustainable Finance: Navigating a Sustainable Future across Logistics, Shipping, and Aviation Industries”, focused on how ESG (environmental, social and governance) is reshaping operational models and development directions in the logistics, maritime and aviation sectors. Patrick Lau, Deputy Executive Director of the HKTDC, gave the Opening Address at the workshop, followed by industry experts including KT Ting, Chief Operating Officer, Hong Kong Quality Assurance Agency; Calvin Chung, Director, Chimbusco Pan Nation; Wai Yeung Tam, Senior Finance Manager, SF REIT Asset Management Limited; and Eric Liu, Chief Executive, Cathay United Bank Hong Kong Branch. They discussed challenges and opportunities in the industry’s green transformation and addressed the important role of sustainable finance to support enterprises in the transition.As the world strives towards net-zero emissions, Hong Kong is committed to developing as a green maritime centre. The recent Policy Address proposes establishing Hong Kong as a green marine fuel bunkering centre, focusing on green methanol, green ammonia and hydrogen. A session titled “Green Energy Forum: Fuels, Freight, and the Road to Net Zero” will be held tomorrow (18 November) to share pathways, challenges and opportunities for a more sustainable and low-carbon future. Speakers include Essam Al Sheibany, Vice President Sustainability, Asyad Group; Tryggvi Thor Herbertsson, Head of Hydrogen Strategy and Partnership, Qair Group; James Laybourn, Regional Segment Director, APAC, DNV Energy Systems; and Wu Yi, Deputy General Manager, Kunlun Energy Co., Ltd.ALMAC offers a rich and diverse programme for participants, with tomorrow’s highlighted sessions, including the Hong Kong Authorized Economic Operator (AEO) Programme, the Supply Chain Management and Logistics Panel, “Logtech Forum: Stay Ahead in the Next Wave of Supply Chain Innovation”, and the Youth Empowerment Workshop. Representatives from companies such as HP, Reckitt, DHL Express, LALAMOVE and Procter & Gamble will share valuable insights and practical skills, helping participants stay ahead of the latest industry developments.The 15th Asian Logistics, Maritime and Aviation ConferenceDate17 and 18 November 2025 (Monday and Tuesday)VenueHall 3FG, HKCECWebsitesALMAC: https://almac.hktdc.com/conference/almac/enProgramme: https://almac.hktdc.com/conference/almac/en/programmeSpeaker list: https://almac.hktdc.com/conference/almac/en/speakerPhoto download: https://bit.ly/4ojiKsFThe 15th Asian Logistics, Maritime and Aviation Conference (ALMAC), organised by the HKSAR Government and the HKTDC, opened today. Under the theme “Collaboration and Growth in the New Trade Landscape”, the event brings over 80 heavyweight speakers to explore industry trends and opportunitiesJohn Lee, Chief Executive of the HKSAR, attended the first day of the conference to deliver a Special AddressSophia Chong, Executive Director of the HKTDC, delivered welcome remarks at the Opening SessionBusiness-matching sessions at ALMAC are connecting shippers with service providers to foster regional partnerships and drive industry growthThe Low-altitude Economy zone made its debut at this year’s ALMAC Exhibition, demonstrating cutting-edge technologies and applications in drones, unmanned aerial vehicles and urban air mobilityThe session titled “Steering Business Growth in a New Era of Global Trade” explored the ripple effects of evolving trade policies and the impact of rising economic fragmentationIn the session “Tapping the Middle East: Logistics, Innovation & Trade Potentials”, industry leaders from the Middle East shared the huge opportunities and transformation potential in logistics and supply chainsMedia enquiriesYuan Tung Financial Relations:Louise SongTel: (852) 3428 5690Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Johnny TsuiTel: (852) 2584 4395Email: johnny.cy.tsui@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

The updated study incorporates redesigned dry-stack tailings system engineered to eliminate acid mine drainage and is one of the final ESIA reports.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - November 17, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects, is pleased to announce that it has commissioned an updated Air Dispersion Modelling and Dust Management Study (the "Study") for its 100%-wholly owned Lac Knife Project (the "Project") in Quebec. This work represents one of the final environmental studies required to complete the Environmental and Social Impact Assessment ("ESIA") and advance the Project toward mine-permitting readiness.The Study will be led by WSP Canada Inc. ("WSP"), a world-leading Montreal-based global engineering, environmental, and professional-services consultancy, and will be conducted under the supervision and management of IOS Geosciences Inc. ("IOS"), the Company's geological consultant and general contractor for the Project. WSP includes the former Woods Engineering, which participated in the 2019 preliminary design of the dry-stack tailings storage facility ("TSF"), as well as Golder Inc., which conducted the original 2014 Study.The Study will evaluate the potential airborne dispersion of dust and gases associated with mining operations, including:wind-driven erosion from the TSF,emissions generated by blasting activities, andtraffic-related dust along the 7-kilometre access road linking Lac Knife to Highway 389.This updated modelling replaces the earlier 2014 study to reflect the re-engineered dry-stack tailings design, developed as part of the 2021 Feasibility Study (the "Feasibility") update. The redesign eliminates the former wet-pond configuration and instead utilizes dolomitic marble to amend and encapsulate tailings, thereby preventing acid mind drainage ("AMD") and metal leaching. This new TSF concept was considered material enough to necessitate remodelling of the areal dispersion.The current program directly addresses follow-up questions from Quebec's Ministry of Sustainable Development, Environment, and the Fight Against Climate Change ("MDDELCC"), issued during its review of the Company's 2014 ESIA submission. Results from the Study are expected by February 2026, aligning with the planned submission of the final revised ESIA."The completion of the air dispersion modelling and dust management plan marks one of the last major technical steps in our environmental review process," said Dean Hanisch, Chief Executive Officer of Focus Graphite. "We are now systematically finalizing outstanding ESIA components to move Lac Knife toward the permitting stage. Each of these studies reflects our ongoing commitment to advance the Project responsibly."Qualified PersonThe technical content disclosed in this news release was reviewed and approved by Rejean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About WSP Canada Inc.WSP Canada Inc. is a Canadian subsidiary of WSP Global Inc., one of the world's leading professional-services firms. Headquartered in Montreal, Quebec, WSP provides multidisciplinary engineering, environmental, and consulting services across the infrastructure, energy, mining, transportation, and built-environment sectors. With thousands of professionals across Canada and internationally, WSP delivers technical excellence and sustainable solutions supporting clients through every stage of project development.For more information on WSP Canada Inc. please visit https://www.wsp.com/en-ca/ About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Focus Graphite's flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Focus Graphite's Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, they go beyond mining – we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Focus Graphite's commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals – reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comLinkedIn: https://www.linkedin.com/company/focus-graphite/ X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated timing, scope, and results of the Air Dispersion Modelling and Dust Management Study (the "Study") at the Lac Knife Project; the completion of the Company's Environmental and Social Impact Assessment ("ESIA") and related technical studies, including hydrogeological and tailings dam analyses; the expected timing of regulatory submissions and approvals; the potential for the Project to achieve mine-permitting readiness; and the advancement of the Lac Knife Project toward development. Forward-looking information also includes statements regarding the Company's expectations concerning the effectiveness of the redesigned dry-stack tailings storage facility, the ability to meet Québec's environmental and regulatory standards, the anticipated role of the Lac Knife and Lac Tetepisca projects within Canada's Critical Minerals Strategy, and the Company's capacity to secure the financing and partnerships required to advance these projects responsibly and sustainably.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274738 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) – iRad Hospital, the pioneering resort medical facility located at Studio City, today announced the signing of a cooperation agreement with Hong Kong Sanatorium & Hospital. This partnership launches comprehensive cross-border medical concierge services, reinforcing the Macau government's "1+4" moderate economic diversification framework and supporting Macau's emergence as a medical tourism destination.This strategic alliance enables seamless connectivity of medical services between the two regions, providing patients with access to expanded specialty medical resources through iRad's medical concierge platform.Combining Hong Kong Sanatorium & Hospital's 103-year legacy of comprehensive medical excellence with iRad's over 20 years of professional medical experience and resort-integrated healthcare model, this partnership establishes an unprecedented healthcare network covering the Pearl River Delta region.The medical concierge program facilitates integrated care coordination, efficient cross-institutional scheduling, and personalized treatment plans utilizing resources from both institutions. This comprehensive approach ensures seamless continuity of care, delivering better clinical outcomes for patients seeking medical services in the region.Mr. Lawrence Ho, Founder of Black Spade Capital and Chairman & CEO of Melco, stated, "The collaboration between iRad and Hong Kong Sanatorium & Hospital demonstrates our commitment to advancing Macau's '1+4' industrial transformation agenda, creating vital healthcare connections between the two regions, enriching Studio City's health tourism offerings while expanding healthcare options for the Greater Bay Area community."Mr. Wyman Li, Chief Operating Officer of HKSH Medical Group, remarked, "Partnering with iRad reflects our vision of borderless healthcare, bringing exceptional value to patients in both markets, developing new approaches for the Greater Bay Area, and further deepening collaborative innovation across various sectors within the region."Photo caption: (From left to right) HKSH Head of Business Development Mr. Wei-Hsu Chen, iRad Hospital Founder & Chairman Dr. Matthew Ngan, HKSH Medical Group Chief Operating Officer Mr. Wyman Li, Black Spade Capital Founder and Melco Chairman & CEO Mr. Lawrence Ho, Black Spade Capital CEO and iRad Hospital Honorary Chairman Mr. Dennis Tam, HKSH Assistant Medical Superintendent Dr. Lau Chor Chiu, and iRad Hospital CEO Mr. Kin Wong celebrate the strategic partnership between iRad Hospital and Hong Kong Sanatorium & Hospital.About HKSH Medical GroupOfficially launched in September 2017, HKSH Medical Group promotes public health and advanced medicine through a multi-faceted, coordinated approach across clinical services, medical education, scientific research and public health education. Members of the Group, including Hong Kong Sanatorium & Hospital, HKSH Healthcare and HKSH Eastern Medical Centre, are dedicated to offering top-quality holistic care to patients, upholding the motto “Quality in Service, Excellence in Care.”Hong Kong Sanatorium & Hospital is a key member of HKSH Medical Group. Established in 1922, it is one of the leading private hospitals in Hong Kong. Living up to its motto of “Quality in Service Excellence in Care,” the Hospital is committed to serving the public as well as promoting medical education and research.For more information about HKSH Medical Group, please visit www.hksh.com.About iRad Medical Group—Hong Kong's Largest MRI Diagnostic Service ProviderEstablished in 2005, iRad is a trusted leader in diagnostic radiology across Hong Kong. Black Spade Capital has been iRad Medical's controlling shareholder since 2021. As at 2024, iRad was the largest MRI diagnostic services provider in Hong Kong by revenue and by the number of MRI scanners. Focused on delivering high-quality imaging services and exceptional patient care, the Group's strong and extensive client base includes the Government of the Hong Kong SAR, as well as other high-profile medical groups, corporations, private doctors and NGOs. Meanwhile, iRad Hospital is the first and largest private medical imaging and examination service provider within an integrated resort in Macau, making iRad Group the first medical imaging group in the world to offer comprehensive private imaging and examination services, including MRI and CT services, to the integrated resort industry.Media Enquiries:Strategic Financial Relations LimitedVicky LeeTel: +852 2864 4834Email: vicky.lee@sprg.com.hk Iris Au YeungTel: +852 2114 4913Email: iris.auyeung@sprg.com.hkWebsite: www.sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年11月17日 - (亚太商訊) - 位于新濠影汇的开创性度假村医疗设施卓智医院（iRad），今日宣布与香港养和医院签订合作协议。此次合作推出全方位跨境医疗礼宾服务，强化澳门政府「1+4」产业适度多元发展框架，助力澳门成为新兴医疗旅游目的地。这项战略联盟实现两地医疗服务的无缝连接，透过iRad的医疗礼宾平台为患者提供更多专科医疗资源。 结合香港养和医院103年深厚的综合医疗传承与iRad逾20年的专业医疗经验及度假村融合医疗模式，此伙伴关系建立起覆盖珠江三角洲地区前所未有的医疗网络。医疗礼宾计划促进综合护理协调、跨机构高效排程，以及运用双方机构资源制定的个人化治疗方案。这种全面的方式确保护理服务的无缝衔接，为区内寻求医疗服务的患者带来更佳的临床效果。黑桃资本创办人及新濠主席兼行政总裁何猷龙先生表示：「iRad与香港养和医院的合作展现我们推进澳门『1+4』产业转型议程的承诺，在两地之间创建重要的医疗连结，丰富新濠影汇的健康旅游内容，同时扩展大湾区社区的医疗选择。」养和医疗集团营运总监李维文先生表示：「与iRad合作反映我们无界限医疗的愿景，为两地市场的患者带来卓越价值，为大湾区发展新思路，进一步深化湾区内各领域间合作创新。」 图片说明：（左起）香港养和医院业务拓展主管陈威旭先生、卓智医院创办人兼主席颜文煌医生、养和医疗集团营运总监李维文先生、黑桃资本创办人及新濠主席兼行政总裁何猷龙先生、黑桃资本行政总裁及卓智医院荣誉主席谭志伟先生、香港养和医院副院长刘楚钊医生，以及卓智医院首席执行官黄建丰先生，共同庆祝卓智医院与香港养和医院达成战略伙伴关系。 关于养和医疗集团养和医疗集团于 2017 年 9 月正式启动，旗下成员分别有养和医院、养和医健、养和东区医疗中心及养和癌症中心。养和医疗集团以全方位策略，透过优质临床医疗服务、医学教育和科研，以及公众健康教育，推动公共卫生及医学发展，致力为患者提供全人关顾的优质医疗及护理服务。养和医院是养和医疗集团之重要成员，成立于 1922 年，为香港主要私营医院之一，以「优质服务‧卓越护理」为宗旨，致力服务大众，并积极推动医学教育和研究。关于养和医疗集团，请浏览www.hksh.com.关于卓智医疗集团—香港最大的磁力共振诊断服务供应商卓智医疗成立于2005年，是香港放射诊断领域规模领先的医疗集团。黑桃资本自2021年起成为卓智医疗的控股股东。截至2024年，卓智医疗集团凭借营业收入及磁力共振扫描仪数量，成为香港规模最大的磁力共振诊断服务供应商。集团致力提供优质的医学扫描诊断服务及卓越的病人护理，拥有广泛且稳固的客户基础，包括香港特别行政区政府、知名保险公司、具影响力的医疗团体、企业、私人医生和非政府组织。与此同时，卓智医院作为澳门综合度假村内首家且规模最大的私人医学影像与检查服务供应商，使卓智集团成为全球首个为综合度假村产业提供全面私人影像及检查服务（包括磁力共振与电脑断层扫描服务）的医学影像集团。传媒垂询：纵横财经公关顾问有限公司李惠儿电话：+852 2864 4834电邮：vicky.lee@sprg.com.hk 欧阳蔚雯电话：+852 2114 4913电邮：iris.auyeung@sprg.com.hk网址：www.sprg.com.hk Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) – Coinciding with Hong Kong FinTech Week and StartmeupHK Festival, held from November 3 to 7 featuring a series of annual events, the Payment Card Group Limited (“PCG”), a cloud-native payment processor and acquirer, demonstrated its comprehensive business strategy. On November 7, PCG presented its stablecoin settlement pilot program at the Cyberport Venture Capital Forum 2025 (CVCF), demonstrating a technological breakthrough in achieving 5-second cross-border settlement. Additionally, PCG co-organized a forum with the Hong Kong Digital Finance Association (HKDiFi) and shared industry insights on the evolving role of responsible officers. In terms of business development, PCG’s members, Yedpay and BBMSL, have partnered with Visa to launch the “China-Issued Visa Credit Card Instant Discount Program,” helping local merchants expand their mainland customer base. Meanwhile, PCG has continued to promote its “AbbyPay” POS-free digital payment solution at an exchange event with Chiyu Bank and various industry events, driving deeper integration between traditional finance and innovative technology, and demonstrating its forward-looking strategy and industry influence within the digital finance ecosystem.Showcasing stablecoin settlement pilot program at Cyberport Venture Capital Forum 2025On November 7, PCG showcased its latest projects and technological achievements at the Cyberport Venture Capital Forum 2025 (CVCF), including the stablecoin settlement pilot program and the “AbbyPay” POS-free digital payment solution. As the only payment technology company selected in the “Payment & Stablecoin” category under Cyberport’s “Blockchain & Digital Asset Pilot Subsidy Scheme,” PCG launched a stablecoin settlement pilot program with the vision of bridging traditional card payments with Web3 infrastructure. The pilot simulated an Australia-to-Hong Kong transaction using stablecoins within a controlled test environment. Compared to traditional settlement that takes 2 to 3 days and involves high FX and SWIFT costs, stablecoin settlement can be completed under 5 seconds, at 90% lower cost, with on-chain transparency. This solution enables real-time reconciliation, programmable payouts, and cross-border scalability, fully demonstrating the potential of stablecoins to enhance the payment infrastructure.Mr. Michael Hui, Regional Product Director of PCG, stated during the Cyberport’s Blockchain & Digital Asset Pilot Subsidy Scheme use case-sharing session, “With Hong Kong’s Stablecoins Ordinance now in effect, we welcome and support this forward-looking regulatory framework. Thanks to Cyberport, JETCO, our advisors, and industry partners, our pilot program has demonstrated how traditional card payments and Web3 infrastructure can truly come together, achieving stable, efficient, and compliant settlement through blockchain. Looking ahead, we will extend the pilot with merchants across various industries and continue to collaborate with banks, acquirers, and fintech companies to advance industry dialogue and scale adoption, enabling merchants to enjoy faster, more cost-effective, and transparent cross-border payment collections. We believe that with regulated stablecoins, strong compliance, and industry collaboration, Hong Kong is poised to lead the next chapter of digital settlement innovation.”Mr. Michael Hui, Regional Product Director of PCG introduces PCG’s stablecoin settlement pilot program during the Cyberport’s Blockchain & Digital Asset Pilot Subsidy Scheme use case-sharing session.Additionally, Mr. Emil Chan, Advisor of PCG, stated at the panel discussion themed “Stablecoin from a User Perspective: Unlocking New Business Opportunities”, “Stablecoins can bring revolutionary changes to cross-border payments, significantly reducing transaction fees and settlement period. They also enhance financial inclusion, enabling anyone with a smartphone to safely and efficiently access the global market. For merchants, the advantages of stablecoin adoption such as lower fees, instant settlement, and no chargebacks for fraud prevention, can help improve cash flow and attract new customers.”During the panel discussion themed “Stablecoin from a User Perspective: Unlocking New Business Opportunities,” Mr. Emil Chan, Advisor of PCG shares how stablecoins can empower merchants and drive industry transformation.Co-hosting “The New Frontier: ROs as Catalysts for Digital Finance Ecosystems” Forum with Hong Kong Digital Finance AssociationOn the same day, PCG and the Hong Kong Digital Finance Association (HKDiFi) co-hosted an official side event of Hong Kong FinTech Week 2025, “The New Frontier: ROs as Catalysts for Digital Finance Ecosystems” Forum, exploring the new role of responsible officers (ROs) in driving business growth in an increasingly regulated environment. Prof. Emil Chan, Advisor of PCG, and Chairman of the Association of Cloud and Mobile Computing Professionals, remarked, "During PCG's stablecoin settlement research and development process, we witnessed a transformation in the role of ROs. They have evolved from mere compliance gatekeepers into key forces driving innovation. They proactively seek new avenues for innovation, establish frameworks for risk management, build trust with relevant institutions, and set the stage for project success. This shift demonstrates that ROs play a pivotal role in driving success for traditional finance in the digital era."At the Forum, Prof. Emil Chan, Advisor of PCG, and Chairman of the Association of Cloud and Mobile Computing Professionals, Dr. Kenny Siu, Training Director of ESG Academy, Dr. Raymond Chan, Vice Chairman of HKDiFi, and Dr. Hermann Lui, Program Director of Investopedia Institute of Hong Kong, analyze how ROs can redefine their roles to drive business growth.Dialogue with Chiyu Bank senior executives on Hong Kong's digital finance outlookOn October 23, PCG was honored to be invited by the Hong Kong Productivity Council (HKPC) to jointly host senior executives from Chiyu Bank as part of their executive development program centered on “Leadership in Transformation.” Mr. Emil Chan, Advisor of PCG, shared valuable insights on “Opportunities and Challenges in Hong Kong’s Digital Financial Market.” Additionally, PCG team introduced the latest “AbbyPay” POS-free digital payment solution, demonstrating its innovative breakthrough in payment technology. During the event, both parties not only explored the evolving payments landscape in Hong Kong, but also fostered in-depth exchanges between traditional banking expertise and fintech innovation through cross-industry dialogues, driving continuous industry innovation.PCG team engages in a dialogue with Chiyu Bank senior executives to explore the future of digital finance in Hong Kong.Partnering with Visa to help local merchants expand mainland customer baseRecently, PCG members, Yedpay and BBMSL, have partnered with Visa to launch the "China-Issued Visa Credit Card Instant Discount Program." From now until December 31, 2025, China Construction Bank Visa cardholders can enjoy an 8% instant discount on purchases of HK$500 or more at designated stores. Through this initiative, Yedpay and BBMSL aim to help Hong Kong merchants capitalize on the peak shopping season, precisely target high-quality mainland customer segments, and further expand into the mainland market.Yedpay and BBMSL, in partnership with Visa, launch the “China-Issued Visa Credit Card Instant Discount Program” to help Hong Kong merchants capitalize on the peak shopping season and expand their reach into the mainland market."AbbyPay" POS-free digital payment solution receives widespread industry recognitionSince its launch in September, PCG has actively showcased its innovative "AbbyPay" POS-free digital payment solution at various events. In October, PCG introduced "AbbyPay" to investors, industry leaders, and retail technology professionals at the Hong Kong Retail Technology Industry Association's 22nd Anniversary Annual Dinner and the Investment Projects and Talent Matching Fair of the 9th Global Greater Bay Area Sustainable Development Economic and Trade Summit, highlighting how its SoftPOS technology helps eliminate traditional hardware and provide a more convenient and secure payment solution. The enthusiastic response and strong endorsement from participants underscored the solution’s innovative qualities and practical benefits, reinforcing "AbbyPay's" potential in driving industry digital transformation.PCG introduces "AbbyPay" POS-free digital payment solution at the Hong Kong Retail Technology Industry Association's 22nd Anniversary Annual Dinner and the 9th Global Greater Bay Area Sustainable Development Economic and Trade Summit, receiving widespread industry recognition.About The Payment Cards GroupThe Payment Cards Group Limited (“PCG”) is an innovative and leading payment technology company with operations in Hong Kong, Singapore, and the Asia-Pacific region. Established in 2016, PCG has become an acquirer with principal memberships in all major card schemes and e-wallet networks. Yedpay, a member of PCG, has firmly established itself as a digital payment acceptance business in Hong Kong. Meanwhile, A3A, another member of PCG, has developed a cloud-native payment processing platform that operates through RESTful APIs, significantly reducing costs and streamlining complex processes while providing users with real-time transaction data and insights. Furthermore, BBMSL, a core member of PCG, is a payment facilitator, dedicated to offering comprehensive digital payment solutions to Hong Kong’s small and medium-sized enterprises. As an acquiring processor, PCG serves as the backbone infrastructure of the entire payment industry by its Asia’s 1st cloud-based processing and settlement platform. Rooted in Hong Kong with a global vison, PCG seeks to empower merchants with cutting-edge payment technology solutions and drive high-quality development in the global payment ecosystem.For media enquiries, please contact:AJA (IR & Communications)Avy YuTel: (852) 9500 4443Email: avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) – In the context of rapid evolution in the robotics industry, Shoucheng Holdings (0697.HK) is gradually transforming from a traditional infrastructure operator into a new platform company with technological attributes. Its newly released 2025 third-quarter financial report not only demonstrates the company’s solid operating fundamentals, but also clearly conveys its strategic path in the robotics industry chain—from “investment layout” toward “application implementation,” gradually building sustainable long-term growth capability.I. Maintaining High-Speed Growth, with Operating Resilience Further EnhancedThe third-quarter report shows that Shoucheng Holdings’ revenue increased 30% year-on-year to HKD 1.215 billion, while net profit attributable to shareholders rose 22% year-on-year to HKD 488 million. The asset operation business continued to expand, and the asset circulation business maintained high-yield contributions, together forming a stable and predictable operating base for the company.Cash and financial assets reached HKD 8.55 billion, while the asset-liability ratio stood at only 31.5%. The company’s financial structure remains sound, providing sufficient “margin of safety” for new investments and business incubation in robotics. On this steady operating foundation, the company announced a HKD 1 billion share repurchase plan over the next three years, with management demonstrating confidence in corporate value through long-term capital commitment.II. Robotics Enter a Dual-Track Stage of “Investment Deepening + Application Validation”Unlike many market participants who remain at the stage of technology demonstrations or laboratory prototypes, Shoucheng Holdings’ robotics layout already shows a “two-line advancement” pattern:One line upward, deepening investment along the industry chain; One line downward, deploying real application scenarios.(1) Investment deepening: Key industry chain enterprises enter their capital-market sprintThrough its industrial funds, Shoucheng Holdings is investing in humanoid robots, embodied intelligence, flying robots, intelligent perception and other directions, focusing resources on globally competitive enterprises. Recent developments include:Unitree Robotics completing IPO counseling, expected to become the first humanoid robot stock in the A-share market;Yunshengchu completing its shareholding restructuring and officially entering the IPO preparation stage;Multiple enterprises expected to be eligible for listing in 2026.The capital-market progress of these enterprises will bring structural returns to Shoucheng Holdings’ equity investment business and open new space for future profit growth.(2) Application validation: Building a “scenario network” for large-scale robot deploymentTo open the path from “technology” to “commercialization,” Shoucheng Holdings has not stopped at the investment level but has simultaneously built consumer-side and urban-side scenario networks. Examples include:The “Taozhu New Craft Bureau” robot technology experience stores launched in Beijing, Chengdu, and airport landmarks, enabling robots to be “visible, usable, and purchasable”;The “Shoucheng W” robot livestreaming studio, which enhances online reach through real-time demonstrations and consumer conversion models;Pilot deployments of automatic charging robots, surgical robots, and educational robots in education, healthcare, and cultural-tourism scenes.This dual-track structure—investment-driven and scenario-driven—allows Shoucheng to form early-stage resource barriers in “data, users, and demand,” becoming a key foundation for long-term expansion in the robotics sector.III. From High-Speed Growth Toward Long-Term Expansion: 2026 as the Key Inflection PointShoucheng Holdings is entering a critical stage of transitioning from “performance growth” to a “growth logic” model.On the financial side, stable asset operations provide a sufficient safety cushion;On the industrial side, investments, scenario deployments, and capital-market progress in robotics are forming a reinforcing cycle.As Unitree Robotics, Yunshengchu and other core enterprises enter the listing channel—combined with the nationwide rollout of experience stores, commercialization of autonomous charging robots, and expanding humanoid robot applications—the company’s robotics business is expected to enter a “quantifiable contribution phase” in 2026.In other words, over the past two years, Shoucheng Holdings has focused on building “infrastructure,” while in the coming years, it will begin to demonstrate “long-term growth attributes.”Based on a foundation of solid financials and forward-looking industrial layout, Shoucheng Holdings is gradually forming a dual-engine model of “robotics investment + application.” As the industry approaches the window of scenario scale-up, the company is already positioned strategically. High-speed growth is the present; long-term growth is the direction. For Shoucheng Holdings, 2026 may only mark the beginning of a new stage. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年11月17日 - (亚太商訊) - 在机器人产业快速演进的当下，首程控股（0697.HK）正在从传统基础设施运营商，逐步转型为具备科技属性的新型平台公司。其最新发布的2025年第三季度财报，不仅展现了公司稳健的经营基本面，也清晰传递出其在机器人产业链上的战略路径——从"投资布局"迈向"应用落地"，并逐步构建可持续的长期成长能力。一、业绩保持高速增长，经营韧性进一步增强三季报显示，首程控股收入同比增长30%至12.15亿港元，归母净利润同比提升22%至4.88亿港元。资产运营业务持续扩张，资产融通业务保持高收益贡献，合计形成公司稳定、可预期的经营底盘。现金与理财资产规模达到85亿港元，资产负债率仅31.5%，财务结构稳健，这为公司进入机器人领域的新投资与新业务孵化提供了足够的"安全边际"。在稳健经营基础上，公司宣布未来三年实施10亿港元股份回购，管理层通过长期资金承诺进一步验证了对公司价值的信心。二、机器人进入"投资深化+应用验证"双轨阶段与大多数停留在技术展示或实验室阶段的市场参与者不同，首程控股的机器人布局已呈现"双线推进"的特征：一端向上，深耕产业链投资；一端向下，布局实际应用场景。（1）投资深化：产业链关键企业陆续进入资本化冲刺期首程控股通过旗下产业基金布局人形机器人、具身智能、飞行机器人、智能感知等方向，并将资源集中在具备全球竞争力的企业。近期进展包括：宇树科技完成IPO上市辅导，有望成为A股人形机器人第一股；云深处完成股改，正式进入上市筹备阶段；多家企业在2026年具备登陆资本市场的条件。这些企业的资本化进程，将为首程控股的股权投资业务带来结构性收益，为未来利润增长打开新增空间。（2）应用验证：构建机器人大规模落地的"场景网络"为了打通机器人从"技术"到"商业"的通路，首程控股并未止步于投资端，而是同步搭建消费和城市端的场景网络。例如："陶朱新造局"机器人科技体验店在北京、成都及机场等多个地标落地，实现机器人"看得见、用得上、买得到"；"首程W"机器人直播间以实时展示与消费转化模型，补齐线上触达能力；在教育、医疗、文旅等场景中推进自动充电机器人、手术机器人、教学机器人等落地试点。投资驱动与场景驱动的双轨结构，使首程能够在机器人产业的早期阶段形成"数据、用户、需求"三类资源壁垒，构成长线增长的重要基础。三、从高速增长迈向长期成长：2026年将成为关键分界线首程控股正经历从"业绩增长"向"成长逻辑"转变的关键阶段。财务端，公司以稳健资产运营提供足够安全垫；产业端，机器人业务的投资、应用场景、资本化进展正在形成互相强化的循环。随着宇树科技、云深处等核心企业进入上市通道，加之体验店全国布局、自动充电机器人商用化、人形机器人应用不断丰富，公司机器人业务预计将在2026年进入"可量化贡献期"。换句话说，过去两年首程控股着力构建的是"基础设施"；而未来几年，将开始体现"长期成长性"。首程控股以稳健财务与产业前瞻布局为基础，逐步形成"机器人投资+应用"双轮驱动的商业模型。在行业即将迎来场景放量的窗口期，公司已处在结构性优势位置。高速增长是现状，长期成长是方向，2026年对首程控股而言，或许只是一个全新阶段的开始。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年11月17日 - (亚太商訊) - 创新实业集团有限公司（简称“创新实业”，股份代号：02788.HK）已正式启动招股，招股时间为11月14日至11月19日，全球发售共计5亿股股份，发售价介乎每股10.18港元至10.99港元，最高集资54.95亿港元。此次招股，创新实业每手认购单位为500股，入场费约为5,550港元，11月19日截止招股，预计11月24日正式挂牌上市。中金公司与华泰国际为联席保荐人。依托区域资源优势，构筑电解铝产业链一体化生态创新实业专注于氧化铝精炼及电解铝冶炼业务，是中国铝产业链上游的核心参与者。自2012年起，创新实业持续依托内蒙古和山东两地的区域资源与产业布局优势，构建了高自给率，强互补性及协同性的电解铝产业链一体化生态系统，覆盖能源、氧化铝精炼、电解铝冶炼。据CRU报告，按2024年产量计，公司位于内蒙古霍林郭勒的电解铝冶炼厂为华北第四大电解铝生产基地，公司为中国第十二大电解铝生产商。公司位于内蒙古的子公司内蒙创源于2024年获工信部授予国家级绿色工厂荣誉。在能源环节，公司已建立自有火力发电站和发电设施，并正加快建设以绿电为主的发电站及发电设施，为生产提供低成本且稳定的电力保障。根据CRU报告，2024年公司电力自给率约为88%，且显著高于约57%同业平均水平，充分体现出其在成本控制与供应安全方面的领先优势。财务表现稳健增长 盈利能力持续增强创新实业财务基础稳健，收入与利润均保持强劲增长势头。根据招股书显示，公司总收入由2022年的人民币134.90亿元增长至2024年的人民币151.63亿元，年复合增长率约为6.0%。截至2025年5月31日止前五个月，公司录得收入人民币72.14亿元，同比上升22.6%，显示出持续增长动能。盈利能力方面，公司实现质的飞跃。净利润由2022年的人民币9.13亿元大幅跃升至2024年的人民币26.30亿元，年复合增长率超过60%。这一显著提升主要得益于成本结构优化与规模效应的释放。公司毛利率在2024年上升至28.2%，较往年水平显著改善，反映出其产业链一体化模式在成本波动周期中的稳定性与高效性。截至2025年前五个月，公司净利润为人民币8.56亿元，盈利表现依然稳健。锚定全球化布局 开启价值新篇面对国内电解铝产能逐步接近政策上限的行业格局，创新实业前瞻性地将发展视野延伸至全球市场，重点把握“一带一路”沿线国家在新能源及基础设施建设方面对铝产品的强劲需求。公司正积极推进沙特阿拉伯50万吨电解铝产业链综合项目。该项目依托沙特丰富的能源资源与低成本电力，预计投产后生产成本将低于全球平均水平，有望成为公司全球化布局的重要支撑点。根据招股书显示，本次募集资金的50%将用于拓展海外产能，包括建设一家电解铝冶炼厂及购买及安装生产设施；40%将用于建设绿色能源项目；10%将用于补充营运资金及一般公司用途。未来，创新实业将持续依托其资源禀赋和产业链协同优势，在巩固国内核心产能的同时，加快海外战略布局步伐。公司将以稳健的财务管理和卓越的运营效率，为股东与投资者创造可持续的长期价值，推动中国铝工业迈向更高质量的发展阶段。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

DUBAI, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) - On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard.The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components."The completion of our full-scale fatigue test validates years of GA-ASI design and analysis efforts," said GA-ASI President David R. Alexander. "The first two lifetimes simulated the operation of the aircraft under normal conditions, and the third intentionally inflicted damage to the airframe's critical components to demonstrate its ability to tolerate operational damage that could occur over the lifetime of the aircraft."Testing was conducted from December 13, 2022, through October 31, 2025, at Wichita State University's National Institute for Aviation Research in Wichita, Kansas. The airframe tested was a production airframe purpose-built to support the test campaign.MQ-9B is GA-ASI's most advanced RPA and includes the SkyGuardian® and SeaGuardian® models as well as the new Protector RG Mk1 that is currently being delivered to the United Kingdom's Royal Air Force (RAF). In addition to the RAF, GA-ASI has MQ-9B procurement contracts with Belgium, Canada, Japan, Taiwan, Poland, India, Denmark, and the U.S. Air Force in support of the Special Operations Command. MQ-9B has also been featured in various U.S. Navy exercises, including Northern Edge, Integrated Battle Problem, RIMPAC, and Group Sail.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com